A carregar...
免疫检查点抑制剂治疗EGFR突变非小细胞肺癌的研究进展
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Na minha lista:
| Publicado no: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
中国肺癌杂志编辑部
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6105349/ https://ncbi.nlm.nih.gov/pubmed/30172273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|